Research Analysts Set Expectations for AURA Q1 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Aura Biosciences in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will post earnings of ($0.44) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q2 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.87) EPS and FY2026 earnings at ($2.11) EPS.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09).

Separately, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Aura Biosciences currently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Stock Performance

Shares of Aura Biosciences stock opened at $6.34 on Thursday. The company has a fifty day moving average of $7.54 and a 200 day moving average of $8.61. The company has a market capitalization of $316.69 million, a P/E ratio of -3.66 and a beta of 0.30. Aura Biosciences has a fifty-two week low of $5.77 and a fifty-two week high of $12.38.

Institutional Trading of Aura Biosciences

Several hedge funds have recently made changes to their positions in AURA. Long Focus Capital Management LLC increased its stake in Aura Biosciences by 123.9% during the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock worth $20,861,000 after acquiring an additional 1,404,228 shares during the last quarter. Levin Capital Strategies L.P. increased its position in shares of Aura Biosciences by 169.1% during the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock valued at $10,255,000 after purchasing an additional 783,984 shares during the last quarter. B Group Inc. purchased a new stake in Aura Biosciences during the 4th quarter valued at $3,885,000. Franklin Resources Inc. raised its holdings in Aura Biosciences by 14.8% during the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after buying an additional 215,597 shares during the period. Finally, Ensign Peak Advisors Inc lifted its position in Aura Biosciences by 43.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock worth $3,212,000 after buying an additional 118,000 shares during the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 23,045 shares of company stock worth $177,242 in the last quarter. 5.40% of the stock is owned by corporate insiders.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.